Background: Hormone receptor-positive (HR+), HER2− negative metastatic breast cancer (MBC) is the most common subtype of advanced breast cancer. Resistance to endocrine therapy often develops, particularly after CDK4/6 inhibitors. Everolimus, an mTOR inhibitor, may restore hormone sensitivity, but real-world data after CDK4/6 and chemotherapy are limited. Methods: This retrospective, single-center study included 70 patients with HR+/HER2− MBC who progressed on CDK4/6 inhibitors and at least one line of chemotherapy. All received daily oral everolimus (10 mg) plus exemestane (25 mg). Tumor response was assessed via RECIST v1.1, and survival outcomes were estimated using the Kaplan–Meier method. Results: Median progression-free survival was 6.6 months and overall survival was 22.6 months. The disease control rate was 88.6%, with 57.1% showing partial response. Fatigue (20%), skin toxicity (8.6%), and stomatitis (5.7%) were the most common adverse events. No grade 3–4 toxicities or discontinuations occurred. No clinical or pathological variables significantly influenced survival. Conclusions: Everolimus plus exemestane provided meaningful clinical benefit and manageable toxicity in heavily pretreated HR+/HER2− MBC patients. This regimen remains a valid later-line option, particularly in settings with limited access to newer targeted therapies or genomic testing.

Background and Objectives: Insomnia is a prevalent yet underrecognized symptom in patients with prostate cancer, and evidence in patients receiving systemic treatment is limited. We assessed the prevalence of insomnia and its associated factors in this population. Materials and Methods: In this two-center, cross-sectional study, insomnia was assessed with the Turkish version of the Insomnia Severity Index (ISI) in patients with metastatic prostate cancer receiving systemic treatment. Insomnia was defined as an ISI score ≥ 8 and clinical insomnia as an ISI score ≥ 15. Results: Among 110 patients, insomnia was present in 52 (47.3%) and clinical insomnia in 15 (13.6%). Pain (adjusted OR, 7.06; 95% CI, 2.31–21.59; p = 0.001) and a higher last prostate-specific antigen (PSA) level (OR per 10-fold increase, 1.47; 95% CI, 1.02–2.12; p = 0.040) were independently associated with insomnia. Clinical insomnia was more frequent in patients with visceral metastasis (50.0% vs. 9.4%; p = 0.008). Insomnia did not differ by treatment group or time on androgen deprivation therapy. Conclusions: Nearly half of these patients have insomnia, associated mainly with pain and active disease. Routine insomnia screening and pain management are warranted.